by Raynovich Rod | Apr 24, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 4/25…MRK up over 3% on confirmed guidance Revs at $63-64B,EPS $8.53-8.65, Junuvia drug on Medicare IRA targeted list, gains on blockbuster Keytruda Q1 sales of $6.9B. Anxious mood from META earnings, inflation and weak GDP scare investors but recovers....
by Raynovich Rod | Apr 15, 2024 | 2023-24 Life Science Portfolios
Update-2…4/18…Sellers may be going away but buyers are still in hiding. XLV flat at $138.49, IBB down 0.99%, XBI down 1.385 at $83.48.UNH continues recovery up 2.96% at $493. Choppy tape with a reddish screen. Noted weakness in chip stocks with AMAT down...
by Raynovich Rod | Mar 31, 2024 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-3 4/5/24 Steady gains with a lot of green. Small cap life science 2+% gains: CRMD, CRNX, CYTK,GERN, NTRA,RXRX,TWST. XBI holding at $90 level. Update-2 4/4/24 Stocks reversed after some early strength as small caps and momentum trades took a hit. Selling picked...
by Raynovich Rod | Mar 25, 2024 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-1 MRK up 5% to $131.81 on FDA approval of PAH (Pulmonary Arterial Hypertension) Drug. ABBV and LLY get small gains SUPN up 3.88%. Nice pick-up in momentum from our SMID trading list: ABOS, CPRX, CRMD, CYRX, PACB, ROIV,, VCEL, VCYT, etc, XBI up 2.38%. XLV...
by Raynovich Rod | Mar 20, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 JY 20 at the close after Powell and the FED announced rates remain unchanged with 3 planned rate cuts expected in 2024. Inflation remains sticky in a strong economy. All major indices hit new highs. XBI held the $94 anticipated support up 0ver 1% to $95 at...
by Raynovich Rod | Mar 11, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-4 3/19..2:40p EDT..Stealth rally pre-FED day, call it an AI rally as all major indices are up. 10 year at 4.295%.If TSY yields stays down then small caps can follow: SMID Biotechs UP today are :CRBU, CBRX, CRMD,CYRX, PACB, SUPN etc with some buying in XBI at...
by Raynovich Rod | Mar 4, 2024 | 2023-24 Life Science Portfolios
Update-3 3/6/2..The XBI huffed and puffed but could not break out from $100 today so my call stands that speculating in SMID biotechs is risk off. The less volatile IBB held near the $138 level. I’ll update our trading list at the end of the week but for now...
by Raynovich Rod | Feb 26, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
3/1/24…Still plenty of good biotech trades around as XBI recovers over 3% to $101.53. Big movers today were: ABOS, CRMD, DNLI, GERN, IMTX, SUPN. https://www.nasdaq.com/market-activity/etf/xbi/advanced-charting 2/29 at close ..MOmentum is easing with volatility...
by Raynovich Rod | Feb 20, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-1 2/23/24. You know the story by now it’s all about AI and NVDA. As my friend said in the mid -90s “there is no end to chips Rod”. Overall one of the best weeks for the market but of course led by technology stocks. The equal weight small cap...
by Raynovich Rod | Feb 5, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Healthcare and Life Science Funds and ETFs Healthcare stocks usually provide a defensive posture to a stock portfolio. SMID biotech stocks have been in a bear market since late 2021 but they are coming back since late 2023. So the weighting of large cap biophharma...
